文献速递炎症性肠病

全国炎症性肠病患者队列中硫嘌呤所致严重骨髓抑制的发生率

Incidence of Thiopurine-Induced Severe Myelosuppression in a Nationwide Cohort of Patients With Inflammatory Bowel Disease.
PubMed 文献 · Am J Gastroenterol · 2024-10-18

该研究利用退伍军人事务医疗系统数据,纳入73,392例炎症性肠病患者,其中14,760例接受硫嘌呤治疗,2,823例硫嘌呤S-甲基转移酶水平正常。严重硫嘌呤诱导的骨髓抑制发生率为每1,000患者年1.25例,发生率很低,对长期频繁全血细胞计数监测的必要性提出疑问。

要点

  • 在2,823例硫嘌呤S-甲基转移酶正常的炎症性肠病患者中,严重骨髓抑制发生率为每1,000患者年1.25例。
  • 严重硫嘌呤诱导的骨髓抑制发生率很低。
  • 作者对硫嘌呤治疗患者长期频繁全血细胞计数监测的必要性提出疑问。

核心结论

  • 严重硫嘌呤诱导的骨髓抑制发生率很低,对炎症性肠病患者长期频繁全血细胞计数监测的必要性提出疑问。

研究设计与样本

  • 利用退伍军人事务医疗系统识别接受硫嘌呤治疗6个月且治疗前硫嘌呤S-甲基转移酶水平正常的炎症性肠病患者,评估严重硫嘌呤诱导的骨髓抑制发生情况。

主要发现

  • 在73,392例炎症性肠病患者中,14,760例接受过硫嘌呤治疗,2,823例硫嘌呤S-甲基转移酶水平正常。
  • 严重硫嘌呤诱导的骨髓抑制发生率为每1,000患者年1.25例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There is paucity of data on the incidence of severe thiopurine (TP)-induced myelosuppression (TIM) among patients with inflammatory bowel disease (IBD). METHODS: Using the Veterans Affairs Healthcare System, we identified patients with IBD with normal pretreatment TP S-methyltransferase levels who received TPs for 6 months and developed severe TIM. RESULTS: Among 73,392 patients with IBD, 14,760 had received TPs, and 2,823 had a normal TP S-methyltransferase level. The incidence rate of severe TIM was 1.25 per 1,000 patient-years. DISCUSSION: The incidence of severe TIM was very low, calling into question the necessity of frequent long-term complete blood count monitoring among patients with IBD on TPs.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Khan N, Patel D, Sundararajan R, et al. Incidence of Thiopurine-Induced Severe Myelosuppression in a Nationwide Cohort of Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2024. PMID: 39436267. doi:10.14309/ajg.0000000000003141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。